Showing results (981-990 of 1,142) with videos related to

Sort By:
Pageof 115
The New England Journal of Medicine|November 10, 2025
A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis DTarik Asselah, Michael A Chattergoon, Alina Jucov, et al.
Hepatology (Baltimore, Md.)|June 30, 2015
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infectionJean-Michel Pawlotsky, Robert Flisiak, Shiv K Sarin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 1, 2021
The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infectionYanqin Du, Olympia E Anastasiou, Benedikt Strunz, et al.
Trials|April 2, 2023
BISCIT: Biliary interventions in critically ill patients with secondary sclerosing cholangitis-a study protocol for a multicenter, randomized, controlled parallel group trialKlaus Stahl, Friederike Klein, Torsten Voigtländer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 24, 2025
Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis DeltaPietro Lampertico, Pavel O Bogomolov, Vladimir Chulanov, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Oncogene|December 21, 2018
Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancerMarcel Wiesweg, Stefan Kasper, Karl Worm, et al.
Journal of Viral Hepatitis|October 15, 2013
The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infectionA J van der Meer, B J Veldt, J J Feld, et al.
Hepatology Communications|January 13, 2021
Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHBMaximilian Wübbolding, Juan Carlos Lopez Alfonso, Chun-Yen Lin, et al.
Journal of Gastroenterology and Hepatology|December 10, 2015
Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosisAdriaan J van der Meer, Raoel Maan, Bart J Veldt, et al.
Pageof 115